Compounds > neurotensin (1-10)

Page last updated: 2024-07-31 20:59:29

neurotensin (1-10)

Description

Cross-References

ID Source	ID
PubMed CID	3085266
CHEMBL ID	408658
MeSH ID	M0124203

Synonyms (7)

Synonym
pglu-leu-tyr-glu-asn-lys-pro-arg-arg-pro
l-proline, 1-(n2-(n2-(1-(n2-(n2-(n-(n-(n-(5-oxo-l-prolyl)-l-leucyl)-l-tyrosyl)-l-alpha-glutamyl)-l-asparaginyl)-l-lysyl)-l-prolyl)-l-arginyl)-l-arginyl)-
pyroglutamyl-leucyl-tyrosyl-glutamyl-asparaginyl-lysyl-prolyl-arginy-arginyl-proline
63524-00-5
neurotensin (1-10)
CHEMBL408658
DTXSID30212932

Bioassays (3)

Assay ID	Title	Year	Journal	Article
AID196425	Relative potency expressed in percent to that of neurotensin was measured using rat stomach strips assay	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4 ISSN: 0022-2623	Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.
AID80754	Relative potency expressed in percent to that of neurotensin was measured using guinea pig atria	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4 ISSN: 0022-2623	Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.
AID196904	Relative potency expressed in percent to that of neurotensin was measured using perfused rat heart assay	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4 ISSN: 0022-2623	Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (33.33)	18.7374
1990's	3 (50.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (16.67%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
neurotensin	1	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary	1981	1981	43.0	low	0	1	0	0	0	0

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
haloperidol	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2004	2004	20.0	low	1	0	0	1	0	0
pyrrolidonecarboxylic acid	5	5-oxoproline; L-proline derivative; non-proteinogenic L-alpha-amino acid	algal metabolite	1984	2004	28.8	high	1	1	3	1	0	0
sr141716	1	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist	2004	2004	20.0	low	1	0	0	1	0	0
neurotensin (1-8)	3	peptide zwitterion; peptide	human metabolite	1984	1998	31.3	high	0	1	2	0	0	0
mdl 100907	1			2004	2004	20.0	low	1	0	0	1	0	0
neurotensin	5	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary	1984	2004	28.8	high	1	1	3	1	0	0
neurotensin (1-11)	1			1998	1998	26.0	high	0	0	1	0	0	0
piperidines	1			2004	2004	20.0	low	1	0	0	1	0	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
Dementia Praecox	0	1	2004	2004	20.0	medium	1	0	0	1	0	0
Muscle Contraction	0	1	1981	1981	43.0	medium	0	1	0	0	0	0
Pregnancy	0	1	1998	1998	26.0	medium	0	0	1	0	0	0
Psychoses	0	1	2004	2004	20.0	medium	1	0	0	1	0	0
Psychotic Disorders	0	1	2004	2004	20.0	medium	1	0	0	1	0	0
Schizophrenia	0	1	2004	2004	20.0	medium	1	0	0	1	0	0